6533b871fe1ef96bd12d1c85

RESEARCH PRODUCT

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis

Ignacio LorenzoAbdiel QuinteroCristóbal AguilarEstela GiménezJosé Luis PiñanaCarlos SolanoJuan C. Hernández-boludaAitana Balaguer-rosellóRafael HernaniJuan MontoroManuel GuerreiroJaime SanzJaime SanzMiguel A. SanzMiguel A. SanzAriadna PérezCarlos CarreteroDavid Navarro

subject

medicine.medical_specialtyHaploidentical transplantationCyclophosphamidebusiness.industryUrologyMycophenolatemedicine.diseaseTransplantationGraft-versus-host diseaseSirolimusToxicityMedicineStem cellbusinessmedicine.drug

description

Sirolimus has emerged as an alternative to calcineurin inhibitors-based (CNI) graft-versus-host disease (GVHD) prophylaxis. This retrospective study compares the outcome of 133 consecutive adult patients with haematological malignancies undergoing haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCy) and mycophenolate mofetil (MMF), combined with cyclosporine A (PTCy-CsA-MMF,

yearjournalcountryeditionlanguage
2021-02-14eJHaem
https://doi.org/10.1002/jha2.183